Shares of Illumina, PacBio, Myriad Rise Sharply in January | GenomeWeb

This article has been corrected to fix erroneous information regarding Qiagen. The firm's Q4 revenues increased 5 percent, not decreased 5 percent, as the previous version of the article stated. Also, Qiagen didn't sign a recent companion diagnostic alliance with Amgen.

NEW YORK (GenomeWeb News) – Illumina, Pacific Biosciences, and Myriad Genetics led a group of companies which saw their stocks increase more than 20 percent in January from December as the GenomeWeb Daily News Index rose nearly 7 percent month over month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.